Browse ROR1

Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein. Cell projection, axon
Domain PF01392 Fz domain
PF07679 Immunoglobulin I-set domain
PF00051 Kringle domain
PF07714 Protein tyrosine kinase
Function

Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo (PubMed:25029443). Receptor for ligand WNT5A which activate downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, PubMed:27162350). In inner ear, crucial for spiral ganglion neurons to innervate auditory hair cells (PubMed:27162350).

> Gene Ontology
 
Biological Process GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0007164 establishment of tissue polarity
GO:0016055 Wnt signaling pathway
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0035567 non-canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0090175 regulation of establishment of planar polarity
GO:0198738 cell-cell signaling by wnt
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0015026 coreceptor activity
GO:0017147 Wnt-protein binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0071936 coreceptor activity involved in Wnt signaling pathway
GO:1904929 coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway
Cellular Component GO:0043235 receptor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-4086400: PCP/CE pathway
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-5140745: WNT5A-dependent internalization of FZD2, FZD5 and ROR2
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ROR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ROR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18287027Chronic Lymphocytic LeukemiaPromote immunity (T cell function)Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a Five patients made high-titer antibodies against adenovirus and three made IgG reactive with a leukemia-associated surface antigen, which we identified as ROR1.
28465528Chronic Lymphocytic LeukemiaInhibit immunity (T cell function); essential for immunotherapyWnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. Wnt5a can activate Rho GTPases in chronic lymphocytic leukemia (CLL) cells by inducing the recruitment of ARHGEF2 to ROR1. The capacity of Wnt5a to induce ROR1 to complex with 14-3-3ζ could be blocked in CLL cells by treatment with cirmtuzumab, a humanized mAb targeting ROR1.
22289919Chronic Lymphocytic LeukemiaInhibit immunityA significantly higher frequency of ROR1 expression was found in patients with progressive versus non-progressive disease, and in those with unmutated versus mutated IgVH genes. Cross-linking of anti-ROR1 MAbs using the F(ab')(2) fragments of anti-Fc antibodies significantly augmented apoptosis. Two of the MAbs induced complement-dependent cytotoxicity (CDC) similar to that of rituximab and one anti-ROR1 MAb (KNG) (IgG1) showed killing activity by antibody-dependent cellular cytotoxicity.
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ROR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ROR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0290.922
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7530.253
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5010.355
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8140.113
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5460.736
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1520.565
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7980.195
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8420.459
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8060.5
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3280.638
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1510.188
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.490.0131
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ROR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ROR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ROR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ROR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ROR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ROR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ROR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolROR1
Namereceptor tyrosine kinase-like orphan receptor 1
Aliases NTRKR1; dJ537F10.1; neurotrophic tyrosine kinase, receptor-related 1; Inactive tyrosine-protein kinase trans ......
Chromosomal Location1p31.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ROR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.